Cenobamate in older adults with drug-resistant epilepsy: Real-world tolerability, efficacy, and predictors of discontinuation. (PubMed, Seizure) - Jul 18, 2026 - "CNB is effective and generally well-tolerated in older adults, with most reaching therapeutically meaningful doses. However, an elevated comorbidity burden and advancing age (≥70 years) increase the risk of discontinuation due to adverse effects, underscoring the need for individualized, cautious titration in this vulnerable population."
Journal • Real-world evidence • CNS Disorders • Epilepsy
|
|
Jong Woo Lee; Rani Sarkis; Yeo Jun Yoon
|